Press Releases October 8, 2026 07:00 AM

Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET

Agios Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
AGIO

Agios Pharmaceuticals, a commercial-stage biopharmaceutical company specializing in rare disease treatments, announced it will hold a conference call and webcast on November 5, 2026, to report its third quarter financial results and business highlights.

Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET
AGIO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Agios is focused on developing innovative medicines for rare diseases, combining biological expertise with real-world insights.
  • The company operates in hematology with a growing pipeline of rare disease medicines reflecting patient priorities.
  • Agios maintains engagement and transparency with investors via webcasts, press releases, and SEC filings.

CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Thursday, November 5, 2026, at 8:00 a.m. ET to report its third quarter 2026 financial results and business highlights.

The live webcast will be accessible on the Investors section of the company’s website (www.agios.com) under the “Events & Presentations” tab. A replay of the webcast will be available on the company’s website approximately two hours after the event.

About Agios: Fueled by Connections to Transform Rare Diseases™
At Agios, our vision is to redefine the future of rare disease treatment. Fueled by connections, we build trusted partnerships with communities – collaborating to develop and deliver innovative medicines that have the potential to transform lives. With a foundation in hematology, we combine biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve. Agios is a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. To learn more, visit www.agios.com and follow us on LinkedIn and X.

Available Information about Agios
To achieve broad dissemination, Agios may disclose information to the public through a variety of disclosure channels including press releases, SEC filings, and public conference calls and webcasts. Some of the information distributed through these disclosure channels may be considered material information. Investors and others should note that Agios plans to use its website (www.agios.com) as a distribution channel to announce and give notice of Agios’ upcoming events and presentations (including, but not limited to, presentations at medical or healthcare conferences). Such information, which may be deemed material, will be available on the Investors section of the company’s website under the “Events & Presentations” tab. In addition, you may sign up to automatically receive email alerts about Agios’ upcoming events and presentations (“Calendar Alerts”) by visiting the “Email Alerts” option under the “IR Resources” tab of the Investors section of the company’s website and submitting your email address.

Contacts:
Investor Contact
Morgan Sanford, Vice President, Investor Relations
Agios Pharmaceuticals
[email protected]

Media Contact
Eamonn Nolan, Senior Director, Corporate Communications
Agios Pharmaceuticals
[email protected]


Risks

  • Financial results for Q3 2026 may impact investor sentiment depending on performance against expectations, affecting the biotech sector.
  • Biopharmaceutical R&D and commercialization outcomes carry inherent uncertainties that can affect stock price volatility.
  • Market reaction could be influenced by competitive developments in the rare disease treatment landscape impacting Agios' market position.

More from Press Releases

NN, Inc. Eliminates all of its Preferred Stock Oct 8, 2026 Safe Pro Awarded New AI Subcontract and Launches “SPAI Ground Truth” for Next-Gen Ground Intelligence Oct 8, 2026 Gold.com’s Spectrum Wine Acquires Wine Cellar Club, Expanding Storage Capacity to Approximately 125,000 Cases Oct 8, 2026 Orion Group Holdings to Report Third Quarter 2026 Financial Results on Tuesday, October 27, 2026 Oct 8, 2026 NOVAGOLD Files Third Quarter 2026 Report Unlocking Donlin Gold’s Full Potential and Advancing the Path To Development Oct 8, 2026